Related posts

Investing in Ozempic Stocks – Unlocking the Stock Price Growth PotentialBest Europe Stocks to Buy: Will 2020 See a European Renaissance?26 Stock Top Picks and 3 ETF (Dec 7-13)
Investor Insights

This summary was created by AI, based on 29 opinions in the last 12 months.

Overall, the experts are positive about Novo-Nordisk, particularly highlighting its weight-loss drugs and strong growth potential. However, there are concerns about potential competition, government restrictions, and the long-term side effects of the drugs. The stock has seen significant appreciation, but some experts recommend waiting for a pullback before investing.

Consensus
Positive
Valuation
Fair Value
DON'T BUY
Novo-Nordisk

Doesn't know them well enough nor their drug pipeline. Yes, their weight-loss drug has done well, but he doesn't own this or LLY. Their valuations have priced in the weight-loss drugs. He prefers Amgen, because their weight-loss drug is under trial and not priced into the stock yet. And it trades at a lower PE than these peers.

biotechnology / pharmaceutical
TOP PICK
Novo-Nordisk

Now Europe's most-valuable listed company. Dominant position in growing diabetes and obesity treatment markets. Supplies half the world's insulin. Unprecedented growth. Seeing cardio, kidney and liver benefits from its drugs. Yield is 1%. 

Outpacing broader S&P 500. Technically, very strong. Aging population and rising obesity rates are tailwinds. Seeing ~25% EPS growth rate.

(Analysts’ price target is $141.59)
biotechnology / pharmaceutical
BUY
Novo-Nordisk

The market for weight-loss drugs is projected to be above $50 billion, but take this with a grain of salt. Every 5 years NVO develops a new drug, since they invest well in R&D, like drugs for type 2 diabetes and weight-loss. Expects further growth and would add shares at these levels.

biotechnology / pharmaceutical
SELL
Novo-Nordisk
NVO vs. LLY

Both are just too expensive. NVO is riding the wave of Ozempic, and already seeing a slew of competitive drugs to be released in next few years. LLY has been an incredibly well-run business. He could never buy something with a chart that looks like these, he just has to say he missed it and look for something that will generate returns for clients.

Tough thing with pharma is these drugs are massive successes, you get maybe 12 years of patent protection. Then your biggest success becomes your biggest concern as the patent wears off, and you struggle to find something else. It always happens.

biotechnology / pharmaceutical
BUY
Novo-Nordisk

Good way to get exposure to healthcare. Quality name that is trading at fair price. 

biotechnology / pharmaceutical
BUY
Novo-Nordisk

In the sector, weight loss is the growth area right now. So he'd probably look at LLY and NVO. Those pipelines are probably going to be fairly robust.

biotechnology / pharmaceutical
HOLD
Novo-Nordisk

Sideways since March. Some short-term indicators are turning down. Double top. Could see a bit more weakness, could come back to $110. Longer term, a great stock in biotech. Healthcare is a secular trend. RSI for 5-6 years has been up, and he doesn't see that changing.

biotechnology / pharmaceutical
DON'T BUY
Novo-Nordisk

Great company, but expensive. Lots of promise, but high valuation anticipates great success. He thinks they'll be successful, but you have to be sure you're not paying for that in the stock already. He owns AMGN.

biotechnology / pharmaceutical
BUY
Novo-Nordisk

Recent trend indicating downward pressure. Competition on weight loss drugs making it hard to generate profits. Seasonal perspective - a good time to buy pharma stocks. Expecting stock to appreciate going forward. 

biotechnology / pharmaceutical
PARTIAL BUY
Novo-Nordisk

He's done very well with him. There's more obesity after Covid, and NVO is the leader in these weight-loss drugs. You want to be exposed to this space, but occasionally drug stocks suffer a big correction on news. But the stock is very expensive. Likes it. 

biotechnology / pharmaceutical
PARTIAL BUY
Novo-Nordisk

Has owned this for years, a great compounder. They have a great history of making profits and bringing drugs to market and reinvesting profits. They always look ahead. But this has run up, so start with a half position and add more over time.

biotechnology / pharmaceutical
TOP PICK
Novo-Nordisk

Weight-loss drugs, where there's substantial runway. This one and LLY have a massive lead over everyone else. Could be used to actually prevent diabetes, an absolutely terrible disease. Risks: more competition, short on supply, government restrictions on price charged. Yield is 1.5%.

(Analysts’ price target is $131.89)
biotechnology / pharmaceutical
COMMENT
Novo-Nordisk
Novo vs. LLY

It's too early to tell what the long-term results of the weight-loss drugs, but short term people are buying them. You need to know a lot of tech and chemistry to understand pharma stocks and he doesn't care to do that. If you believe their drug prices will fall and more people will use them, then these share will rise.

biotechnology / pharmaceutical
TOP PICK
Novo-Nordisk

High growth ahead. Europe's most valuable company by market cap. They lead the market in diabetes care, supplying half the world's insulin. Command one-third of the diabetes treatment business. Their weight-loss drug is growing strong which also prevents stroke and drives more demand. The chart is a dream. 18-20% EPS growth lies ahead.

(Analysts’ price target is $131.89)
biotechnology / pharmaceutical
BUY ON WEAKNESS
Novo-Nordisk

It has quality drugs including a weight loss drug and pays a dividend. There are two main risks, one being that insurance companies may not be able to pay for the weight loss drug until the pricing comes down. Also we don't really know what the side effects are and may not know for another five years. You can buy on weakness for exposure to the sector.

biotechnology / pharmaceutical
Showing 1 to 15 of 140 entries

Novo-Nordisk(NVO-N) Rating

Ranking : 5 out of 5

Bullish - Buy Signals / Votes : 17

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 6

Total Signals / Votes : 24

Stockchase rating for Novo-Nordisk is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Novo-Nordisk(NVO-N) Frequently Asked Questions

What is Novo-Nordisk stock symbol?

Novo-Nordisk is a American stock, trading under the symbol NVO-N on the New York Stock Exchange (NVO). It is usually referred to as NYSE:NVO or NVO-N

Is Novo-Nordisk a buy or a sell?

In the last year, 24 stock analysts published opinions about NVO-N. 17 analysts recommended to BUY the stock. 6 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Novo-Nordisk.

Is Novo-Nordisk a good investment or a top pick?

Novo-Nordisk was recommended as a Top Pick by on . Read the latest stock experts ratings for Novo-Nordisk.

Why is Novo-Nordisk stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Novo-Nordisk worth watching?

24 stock analysts on Stockchase covered Novo-Nordisk In the last year. It is a trending stock that is worth watching.

What is Novo-Nordisk stock price?

On 2024-07-25, Novo-Nordisk (NVO-N) stock closed at a price of $129.635.